Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999
Authors:
- A MocroftAMA Mocroft
- F AntunesF Antunes
- for the EuroSIDA Study GroupFGfor the EuroSIDA Study Group
Open Access
- 10 January 2008
- journal article
- Published by Wiley in HIV Medicine
- Vol. 9 (1) , 41-46
Abstract
Regional differences across Europe in triple class failure (TCF; the failure of each of the three separate main classes of antiretrovirals (ARVs) with a viral load >1000 HIV‐1 RNA copies/mL for >4 months) have not been described. A total of 1956 patients started combination ARV therapy after 1 January 1999, of whom 123 patients developed TCF [6.3%; incidence 16.7 per 1000 person‐years of follow‐up; 95% confidence interval (CI) 13.7–19.6]. After adjustment, patients from Eastern Europe had a significantly increased incidence of TCF compared with patients from Southern Europe/Argentina (3.05; 95% CI 1.36–6.82; P=0.0067) while patients taking either a boosted protease inhibitor regimen (0.33; 95% CI 0.15–0.74; P=0.0072) or a nonnucleotide reverse transcriptase inhibitor (NNRTI)‐based regimen (0.59; 95% CI 0.37–0.94; P=0.026) had a reduced incidence of TCF.Keywords
This publication has 9 references indexed in Scilit:
- Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across EuropeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral TherapyArchives of internal medicine (1960), 2006
- Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individualsAIDS, 2005
- Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study GroupThe Journal of Infectious Diseases, 2004
- Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classesThe Lancet, 2004
- Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionNew England Journal of Medicine, 2003
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Changes in use of antiretroviral therapy in regions of Europe over timeAIDS, 1998